NCT05441189View on ClinicalTrials.gov

Precise Gene Signature for Predicting Outcomes in PDAC

CompletedOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

April 19, 2021

Primary Completion Date

May 1, 2022

Study Completion Date

June 22, 2022

Conditions
Stage I-II Pancreatic Ductal Adenocarcinoma (PDAC)Precise Prognostic and Predictive Signature
Interventions
PROCEDURE

Resection

radical R0 resection of pancreatic adenocarcinoma

Trial Locations (1)

200025

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

The Fourth Affiliated Hospital of Anhui Medical University

OTHER